Apellis Pharmaceuticals shares are trading lower after Citron Research issued a report on the company.
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals' shares are trading lower following a report issued by Citron Research. The report's content and its impact on the company's stock price are not specified.
November 06, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis Pharmaceuticals' stock price is trading lower following a report from Citron Research. The content of the report is not specified.
The stock price of Apellis Pharmaceuticals has fallen due to a report issued by Citron Research. The exact content of the report is not known, but it's clear that the market has reacted negatively to it.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100